- Home
- HIT vs BYSI Comparison
HIT vs BYSI Comparison
Compare HIT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.60
Company Overview
Basic Information| Metric | HIT | BYSI |
|---|---|---|
| Founded | 1964 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 67.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HIT | BYSI |
|---|---|---|
| Price | $1.38 | $1.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 342.0K | 22.2K |
| Earning Date | 03-25-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.39 | N/A |
| Revenue Next Year | $90.58 | N/A |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.98 |
| 52 Week High | $4.01 | $3.44 |
Technical Indicators
Market Signals| Indicator | HIT | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 51.84 |
| Support Level | $1.09 | $1.38 |
| Resistance Level | $1.64 | $1.83 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 15.91 | 43.39 |
Price Performance
Historical Comparison HIT
BYSI
About HIT Health In Tech Inc.
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.